Share:
near term COVID-19 vaccination allocations to follow
TORONTO, May 17, 2021 (GLOBE NEWSWIRE)
Medivolve Inc. ( Medivolve ) ((NEO:MEDV, OTC:COPRF, FRA:4NC)) a healthcare technology and services company, today announced it has signed a binding agreement to acquire 100% of all outstanding shares of Marbella, a nonsterile compounded California state licensed and insured pharmacy. This acquisition advances Medivolve s growth strategy and expands its ability to deliver patient care through immediate access to pharmaceutical distribution throughout the state of California. The acquisition of Marbella Pharmacy is an important step forward in executing on our strategic growth strategy, said David Preiner, CEO of Medivolve. With Marbella, we have access to distribute pharmaceuticals, and soon COVID-19 vaccinations in the fifth-largest economy in the world. We will continue to invest in the resources and partnerships that advance our mission to harness the transformative power
Credit: Medivolve
“You’re going to see who the superspreaders are or who potentially might be spreading the virus more than others,” Medivolve CEO David Preiner said.
Preiner believes the new technology could be a viable substitute for the traditional nasal swab COVID-19 test and could be used in drive-through testing or within schools.
“It makes it very easy to gather samples on a routine basis with no fear of it’s going to hurt,” Preiner explained.
And even as the effects of the pandemic become less prominent, Preiner said COVID-19 testing will still have to be a priority.
“Staying on top of testing even in areas that are asymptomatic I think is critical because the goal is you want to catch a flare-up the moment it pops up,” Preiner said.
Article content
Medivolve is well positioned to deliver shareholder value from its equity position in Marvel Diagnostics and the team’s successful development of BlowFISH, a non-invasive exhaled breath diagnostic technology that has cleared the first milestone in a series of clinical tests and has entered the next phase toward applying for an Emergency Use Authorization from the FDA to use the technology to test for the COVID-19 virus.
TORONTO, May 05, 2021 (GLOBE NEWSWIRE)
Medivolve Inc. (“Medivolve”) (NEO:MEDV; OTC:COPRF; FRA:4NC) a healthcare company that seeks out disruptive technologies, ground-breaking innovations and exclusive partnerships to help combat COVID-19, and Marvel Diagnostics, the developer of the non-invasive exhaled breath diagnostic technology, BlowFISH, announced today that BlowFISH has successfully cleared the first milestone in a series of clinical tests targeting application of an Emergency Use Authorization (EUA) from the United States Food an
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Collection Sites Provides Update With January Sales of 73,973 Tests at an Average Price of $96 .
Medivolve Inc.February 4, 2021 GMT
To date Collection Sites has launched a total of 62 sites across its network with additional new openings in Texas, Florida, and North Carolina. Further, Medivolve will host a webinar today, Thursday, February 4th at 1 pm ET.
TORONTO, Feb. 04, 2021 (GLOBE NEWSWIRE) Medivolve Inc. (“Medivolve” or the “Company”) (NEO:MEDV; OTC:COPRF; FRA:4NC) is pleased to provide investors with a sales update and announces the launch of new COVID-19 testing centres by its wholly owned subsidiary, Collection Sites, LLC. Collection Sites has launched new sites in Texas, Florida, and North Carolina.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Medivolve Enters Into Agreement to Acquire 100% of Noble Bioscience Corp. and Its Agency Rights .
Medivolve Inc.February 2, 2021 GMT
Nuturell’s non-toxic silver surface shield technology is a COVID-19 disinfectant that converts into a protective shield when air dry, killing the coronavirus among other pathogens for up to 90 days after only ~30 seconds of contact. Further, Medivolve will host a webinar Thursday, February 4
th
at 1 pm ET.
TORONTO, Feb. 02, 2021 (GLOBE NEWSWIRE) Medivolve Inc. (“Medivolve”) (NEO:MEDV; OTC:COPRF; FRA:4NC) has entered into an agreement to acquire 100% of Noble Bioscience Corp. (“Noble Bioscience”) in exchange for 12.5 million common shares of Medivolve. Noble Bioscience holds the agency rights to Nuturell’s Surface Shield technology in the United States, Canada and Caribbean countries. Medivolve’s subsidiary Collection Sites, LLC will lead